Pulse Biosciences, Inc. PLSE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pulse Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pulse Biosciences, Inc.'s additional paid-in capital?
- Pulse Biosciences, Inc. (PLSE) reported additional paid-in capital of $548.09M in Q1 2026.
- How has Pulse Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- Pulse Biosciences, Inc.'s additional paid-in capital increased by 4.3% year-over-year, from $525.68M to $548.09M.
- What is the long-term trend for Pulse Biosciences, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Pulse Biosciences, Inc.'s additional paid-in capital has grown at a 22.7% compound annual growth rate (CAGR), from $195.41M to $543.87M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.